Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and .
Tonix Pharmaceuticals Holding Corp.March 15, 2021 GMT
Announced Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia
Interim Analysis Results from Second Confirmatory Phase 3 Study, RALLY, Expected in Third Quarter 2021: Interim Cohort Enrolled
Efficacy Data from Animal Studies of COVID-19 Vaccine Candidate, TNX-1800, Expected in First Quarter 2021
Phase 1 Safety Study in Humans of TNX-1800 Expected to Start in Second Half 2021
At December 31, 2020, Cash and Cash Equivalents Totaled $77.1 Million;
Approximately $110 Million in Gross Proceeds Raised Subsequent to Year-End